Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00637039 |
The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies
Condition | Intervention | Phase |
---|---|---|
Advanced Solid Malignancies |
Drug: AZD8931 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase 1, Open-Label, Multiple-Dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies |
Estimated Enrollment: | 30 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: AstraZeneca Clinical Study Information | 800-236-9933 | information.center@astrazeneca.com |
Contact: AZD8931 Clinical Trials Mailbox | AZD8931ClinicalTrialsMailbox@astrazeneca.com |
Germany | |
Research Site | Recruiting |
Berlin, Germany | |
Russian Federation | |
Research Site | Recruiting |
Moscow, Russian Federation | |
Research Site | Recruiting |
St. Petersburg, Russian Federation |
Principal Investigator: | S. Tjulandin | GU Russian Oncology Research Centre |
Study Director: | Mary Stuart | AstraZeneca |
Study ID Numbers: | D0102C00002, AZD8931 Study 002 |
Study First Received: | March 10, 2008 |
Last Updated: | May 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00637039 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; Russia: Ministry of Health and Social Development of the Russian Federation |
Advanced cancer Solid tumour Solid malignancies Neoplasms |
Neoplasms |